193 related articles for article (PubMed ID: 8936664)
1. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
[TBL] [Abstract][Full Text] [Related]
2. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis.
Namba H; Rubin SA; Fagin JA
Mol Endocrinol; 1990 Oct; 4(10):1474-9. PubMed ID: 2283998
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident.
Nikiforov YE; Nikiforova MN; Gnepp DR; Fagin JA
Oncogene; 1996 Aug; 13(4):687-93. PubMed ID: 8761289
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of RAS point mutations in papillary thyroid carcinoma; a novel mutation at codon 31 of K-RAS.
Cyniak-Magierska A; Brzeziańska E; Januszkiewicz-Caulier J; Jarzab B; Lewiński A
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):594-9. PubMed ID: 17943694
[TBL] [Abstract][Full Text] [Related]
6. N-ras mutation of thyroid tumor with special reference to the follicular type.
Oyama T; Suzuki T; Hara F; Iino Y; Ishida T; Sakamoto A; Nakajima T
Pathol Int; 1995 Jan; 45(1):45-50. PubMed ID: 7704243
[TBL] [Abstract][Full Text] [Related]
7. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G; Zhao H; Camp RL; Pollan M; Herrero A; Pardo J; Wu R; Carcangiu ML; Costa J; Tallini G
J Clin Oncol; 2003 Sep; 21(17):3226-35. PubMed ID: 12947056
[TBL] [Abstract][Full Text] [Related]
8. Ha-ras oncogene (codon 12) mutation in thyroid carcinogenesis: analysis of 60 benign and malignant thyroid tumors.
Bouras M; Parvaz P; Berger N; Paulin C; Revol A
Ann Biol Clin (Paris); 1995; 53(10-11):549-55. PubMed ID: 8787281
[TBL] [Abstract][Full Text] [Related]
9. The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort.
Fukahori M; Yoshida A; Hayashi H; Yoshihara M; Matsukuma S; Sakuma Y; Koizume S; Okamoto N; Kondo T; Masuda M; Miyagi Y
Thyroid; 2012 Jul; 22(7):683-9. PubMed ID: 22650231
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations of the TSH receptor in differentiated thyroid carcinomas.
Russo D; Arturi F; Schlumberger M; Caillou B; Monier R; Filetti S; Suárez HG
Oncogene; 1995 Nov; 11(9):1907-11. PubMed ID: 7478621
[TBL] [Abstract][Full Text] [Related]
11. Selective occurrence of ras mutations in benign and malignant thyroid follicular neoplasms in Taiwan.
Liu RT; Hou CY; You HL; Huang CC; Hock-Liew ; Chou FF; Wang PW; Cheng JT
Thyroid; 2004 Aug; 14(8):616-21. PubMed ID: 15320975
[TBL] [Abstract][Full Text] [Related]
12. Point mutations of ras and Gs alpha subunit genes in thyroid tumors.
Horie H; Yokogoshi Y; Tsuyuguchi M; Saito S
Jpn J Cancer Res; 1995 Aug; 86(8):737-42. PubMed ID: 7559096
[TBL] [Abstract][Full Text] [Related]
13. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
[TBL] [Abstract][Full Text] [Related]
14. G --> A mutation of ras genes and infrequent p53 gene mutation in rat transplantable thyroid carcinoma lines from tumors induced in vivo by N-bis(2-hydroxypropyl)nitrosamine.
Kitahori Y; Naitoh H; Konishi N; Fukushima M; Ohnishi T; Hiasa Y
Cancer Lett; 1996 Feb; 100(1-2):55-62. PubMed ID: 8620454
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Ras mutations in thyroid neoplasia.
Esapa CT; Johnson SJ; Kendall-Taylor P; Lennard TW; Harris PE
Clin Endocrinol (Oxf); 1999 Apr; 50(4):529-35. PubMed ID: 10468914
[TBL] [Abstract][Full Text] [Related]
16. BRAF mutations are not an alternative explanation for the molecular etiology of ras-mutation negative cold thyroid nodules.
Krohn K; Paschke R
Thyroid; 2004 May; 14(5):359-61. PubMed ID: 15186612
[TBL] [Abstract][Full Text] [Related]
17. Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers.
Bouras M; Bertholon J; Dutrieux-Berger N; Parvaz P; Paulin C; Revol A
Eur J Endocrinol; 1998 Aug; 139(2):209-16. PubMed ID: 9724079
[TBL] [Abstract][Full Text] [Related]
18. Structural studies of the thyrotropin receptor and Gs alpha in human thyroid cancers: low prevalence of mutations predicts infrequent involvement in malignant transformation.
Spambalg D; Sharifi N; Elisei R; Gross JL; Medeiros-Neto G; Fagin JA
J Clin Endocrinol Metab; 1996 Nov; 81(11):3898-901. PubMed ID: 8923835
[TBL] [Abstract][Full Text] [Related]
19. Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues.
Capella G; Matias-Guiu X; Ampudia X; de Leiva A; Perucho M; Prat J
Diagn Mol Pathol; 1996 Mar; 5(1):45-52. PubMed ID: 8919545
[TBL] [Abstract][Full Text] [Related]
20. H-ras protooncogene mutations in human thyroid neoplasms.
Namba H; Gutman RA; Matsuo K; Alvarez A; Fagin JA
J Clin Endocrinol Metab; 1990 Jul; 71(1):223-9. PubMed ID: 2196280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
